Inspired by Patients to Improve Outcomes in Systemic Sclerosis

OUR SCIENCE

Our focus on Prostacyclin analogues is based on research establishing PGI2 as a potent vasodilator with antiplatelet, antiproliferative and anti-inflammatory properties

CLINICAL TRIALS

AURORA is a Phase 3 clinical trial evaluating the efficacy and safety of Intravenous iloprost in Systemic Sclerosis

OUR COMMUNITY

We are committed to enriching the lives of Systemic Sclerosis patients through research and education